速効型インスリンの世界市場：市場規模 - 製品別、適応症別、流通チャネル別、地域別展望、競合戦略、セグメント別予測（～2032年）

世界の速効型インスリンの市場規模は、2032年までに118億5,000万米ドルに達し、CAGRで4.90%の成長が予測されています。

ウイルス感染や環境要因、ビタミンD不足、その他の環境変数などにより1型糖尿病が増加していることは、世界の速効型インスリンの必要性を高めている要因です。乳幼児の新生児黄疸症例の増加や診断ツールの進歩も、要因となっています。高齢者人口の増加は、年齢とともに糖尿病のリスクが高まるため、市場の拡大を促進しています。

当レポートでは、世界の速効型インスリン市場について調査し、市場力学、市場変数と見通し、製品・適応症・流通チャネル・地域別の市場分析、企業プロファイル等に関する情報を提供しています。

目次

第1章 イントロダクション

• 調査範囲
• 市場セグメント分析

第2章 調査手法

• 調査データソース
• 市場規模の推定
• データの三角測量

第3章 エグゼクティブサマリー

第4章 市場力学

• 促進要因、抑制要因、機会、課題の分析
  • 促進要因
  • 抑制要因
  • 機会
  • 課題
• 世界の速効型インスリン市場におけるCOVID-19の影響

第5章 市場変数と見通し

• SWOT分析
  • 強み
  • 弱み
  • 機会
  • 脅威
• PESTEL分析
  • 政治情勢
  • 経済情勢
  • 社会情勢
  • 技術情勢
  • 環境情勢
  • 法的情勢
• ポーターのファイブフォース分析
  • 供給企業の交渉力
  • 買い手の交渉力
  • 代替品の脅威
  • 新規参入者の脅威
  • 競合企業間の敵対関係
• ヒートマップ分析

第6章 世界の速効型インスリン市場：製品別、2019年～2032年（100万米ドル）

• リスプロインスリン
• アスパルトインスリン
• グルリシンインスリン

第7章 世界の速効型インスリン市場：適応症別、2019年～2032年（100万米ドル）

• 1型糖尿病
• 2型糖尿病

第8章 世界の速効型インスリン市場：流通チャネル別、2019年～2032年（100万米ドル）

• 病院薬局
• ドラッグストア・小売薬局
• オンラインストア

第9章 世界の速効型インスリン市場：地域別、2019年～2032年（100万米ドル）

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国
  • その他のアジア太平洋
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米
• 中東・アフリカ
  • サウジアラビア王国
  • アラブ首長国連邦
  • その他の中東・アフリカ

第10章 企業プロファイル

• Adocia
  • 企業概要
  • 財務見通し
  • 製品概要
  • 最近の開発
• Biocon Limited
• Eli Lilly
• Gan & Lee Pharmaceuticals Co. Ltd.
• Geropharm
• MannKind Corporation
• Merck & Co. Inc.
• Novo Nordisk A/S
• Sanofi S.A.
• Wockhardt Ltd.

Global Rapid Acting Insulin Market Overview:

According to SPER Market Research, the Rapid Acting Insulin Market is estimated to reach USD 11.85 billion by 2032 with a CAGR of 4.90%.

Rapid acting insulin is a drug that diabetic individuals use to manage their blood sugar levels. It can be inhaled or given intravenously via an insulin pump, prefilled pen, syringe, or other devices. It is given before meals and snacks to lower abnormally high blood sugar levels and boost the amount of bolus insulin. Currently, persons who are unable to reach their postprandial glycemic goals with existing bolus insulins are thought to benefit from new insulin formulations including innovative ultra-fast-acting insulins that improve absorption.

Another reason driving the need for rapid acting insulins throughout the world is the rising prevalence of type-1 diabetes as a result of exposure to viruses and other environmental causes, poor vitamin D levels, and other environmental variables. This is also explained by the rise in neonatal jaundice cases in infants and the advancement of diagnostic tools. Additionally, the growing global elderly population is promoting market expansion since the risk of having diabetes rises with age. Leading market competitors are also producing ready-to-use kits of rapid acting insulin that are quick to administer, offered in vials and pens, and that improve glycemic control in both adults and children. These firms are also concentrating on mergers and acquisitions (M&A), which is projected to aid in the creation of new product versions for the next generation.

Increased investment in research and development (R&D) for human recombinant insulin is anticipated to drive the demand for insulin used in the management of diabetes, thereby boosting the market's growth. The global market for rapid acting insulin is primarily driven by the rise in the prevalence of diabetes on a global scale. Furthermore, because overweight or obese, an unhealthy diet, and physical inactivity, account for nearly 80% of the rise in the incidence of diabetes, sedentary and unhealthy lifestyles double the risk of developing the disease. However, the industry's expansion may be hampered by consumers' hesitation to use quick acting insulin because of adverse effects including hypoglycemia. On the other hand, emerging nations are predicted to provide attractive development prospects for the market for quick acting insulin because of their unexplored markets and undiagnosed population.

Impact of COVID-19 on the Global Rapid Acting Insulin Market

The COVID-19 epidemic, which originated in Wuhan, China, has now spread far over the world. The epidemic is being dealt with by almost all countries. In addition, due to the lockdown scenario imposed by the governments of several nations, the majority of markets have seen a decline. However, it is anticipated that the COVID-19 epidemic would help open up new development potential for businesses involved in the treatment and management of chronic illnesses. Diabetes increases the risk of significant COVID-19 problems, according to a 2020 article by the American Diabetes Association. Additionally, having diabetes together with heart disease or other issues raises the risk of developing significant COVID-19 illness since many illnesses impair a patient's ability to fight the infection. This aided important actors in adopting a variety of tactics to capture the largest possible proportion of the COVID-19 epidemic.

Patients with coronavirus illness (COVID-19) may have an increase in mortality and severity due to diabetes mellitus (DM) and poorly managed blood sugar. This is one of the primary drivers behind the demand for fast-acting insulins to track blood glucose levels.

Scope of the Report:

Market size available for years 2019-2032

Base year considered 2021

Forecast period 2022-2032

Segments covered By Product, By Indication, By Distribution Channel

Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Covered Adocia, Biocon Limited, Eli Lilly, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind Corporation, Merck & Co. Inc., Novo Nordisk A/S, Sanofi S.A., Wockhardt Ltd.

Global Rapid Acting Insulin Market Segmentation:

By Product: Based on the Product, Global Rapid Acting Insulin Market is segmented as; Lispro Insulin, Aspart Insulin, Glulisine Insulin.

By Indication: Based on the Indication, Global Rapid Acting Insulin Market is segmented as; Type 1 Diabetes and Type 2 Diabetes.

By Distribution Channel: Based on the Distribution Channel, Global Rapid Acting Insulin Market is segmented as;

Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Stores.

By Region: The region's rapid acting insulin market was primarily driven by North America and it is predicted that the region would continue to dominate the market as a result of rising diabetes occurrences and an aging population. On the other hand, Asia-Pacific is anticipated to see the greatest growth in the market for quick acting insulin in the coming years due to the spread of obesity and westernised living habits. Over the course of the projection, this is anticipated to drive up demand for quick acting insulin.

Table of Contents

1. Introduction

• 1.1. Scope of the report
• 1.2. Market segment analysis

2. Research Methodology

• 2.1 Research data source
  • 2.1.1 Secondary data
  • 2.1.2 Primary data
  • 2.1.3 SPER's internal database
  • 2.1.4 Premium insight from KOL's
• 2.2 Market size estimation
  • 2.2.1 Top-down and Bottom-up approach
• 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

• 4.1. Driver, Restraint, Opportunity and Challenges analysis
  • 4.1.1 Drivers
  • 4.1.2 Restraints
  • 4.1.3 Opportunities
  • 4.1.4 Challenges
• 4.2. COVID-19 Impacts of the Global Rapid Acting Insulin Market

5. Market variables and outlook

• 5.1. SWOT analysis
  • 5.1.1 Strengths
  • 5.1.2 Weaknesses
  • 5.1.3 Opportunities
  • 5.1.4 Threats
• 5.2. PESTEL analysis
  • 5.2.1 Political landscape
  • 5.2.2 Economic landscape
  • 5.2.3 Social landscape
  • 5.2.4 Technological landscape
  • 5.2.5 Environmental landscape
  • 5.2.6 Legal landscape
• 5.3. PORTER'S five forces analysis
  • 5.3.1 Bargaining power of suppliers
  • 5.3.2 Bargaining power of Buyers
  • 5.3.3 Threat of Substitute
  • 5.3.4 Threat of new entrant
  • 5.3.5 Competitive rivalry
• 5.4. Heat map analysis

6. Global Rapid Acting Insulin Market, By Product, 2019-2032 (USD Million)

• 6.1 Lispro Insulin
• 6.2 Aspart Insulin
• 6.3 Glulisine Insulin

7. Global Rapid Acting Insulin Market, By Indication, 2019-2032 (USD Million)

• 7.1 Type 1 Diabetes
• 7.2 Type 2 Diabetes

8. Global Rapid Acting Insulin Market, By Distribution Channel, 2019-2032 (USD Million)

• 8.1 Hospital Pharmacies
• 8.2 Drug Stores and Retail Pharmacies
• 8.3 Online Stores

9. Global Rapid Acting Insulin Market, By Region, 2019-2032 (USD Million)

• 9.1 North America
  • 9.1.1 United States
  • 9.1.2 Canada
  • 9.1.3 Mexico
• 9.2 Europe
  • 9.2.1 Germany
  • 9.2.2 United Kingdom
  • 9.2.3 France
  • 9.2.4 Italy
  • 9.2.5 Spain
  • 9.2.6 Rest of Europe
• 9.3 Asia-Pacific
  • 9.3.1 China
  • 9.3.2 Japan
  • 9.3.3 India
  • 9.3.4 Australia
  • 9.3.5 South Korea
  • 9.3.6 Rest of Asia-Pacific
• 9.4 South America
  • 9.4.1 Brazil
  • 9.4.2 Argentina
  • 9.4.3 Rest of South America
• 9.5 Middle East & Africa
  • 9.5.1 Kingdom of Saudi Arabia
  • 9.5.2 United Arab Emirates
  • 9.5.3 Rest of Middle East & Africa

10. Company Profiles

• 10.1 Adocia
  • 10.1.1 Company details
  • 10.1.2 Financial outlook
  • 10.1.3 Product summary
  • 10.1.4 Recent developments
• 10.2 Biocon Limited
  • 10.2.1 Company details
  • 10.2.2 Financial outlook
  • 10.2.3 Product summary
  • 10.2.4 Recent developments
• 10.3 Eli Lilly
  • 10.3.1 Company details
  • 10.3.2 Financial outlook
  • 10.3.3 Product summary
  • 10.3.4 Recent developments
• 10.4 Gan & Lee Pharmaceuticals Co. Ltd.
  • 10.4.1 Company details
  • 10.4.2 Financial outlook
  • 10.4.3 Product summary
  • 10.4.4 Recent developments
• 10.5 Geropharm
  • 10.5.1 Company details
  • 10.5.2 Financial outlook
  • 10.5.3 Product summary
  • 10.5.4 Recent developments
• 10.6 MannKind Corporation
  • 10.6.1 Company details
  • 10.6.2 Financial outlook
  • 10.6.3 Product summary
  • 10.6.4 Recent developments
• 10.7 Merck & Co. Inc.
  • 10.7.1 Company details
  • 10.7.2 Financial outlook
  • 10.7.3 Product summary
  • 10.7.4 Recent developments
• 10.8 Novo Nordisk A/S
  • 10.8.1 Company details
  • 10.8.2 Financial outlook
  • 10.8.3 Product summary
  • 10.8.4 Recent developments
• 10.9 Sanofi S.A.
  • 10.9.1 Company details
  • 10.9.2 Financial outlook
  • 10.9.3 Product summary
  • 10.9.4 Recent developments
• 10.10 Wockhardt Ltd.
  • 10.10.1 Company details
  • 10.10.2 Financial outlook
  • 10.10.3 Product summary
  • 10.10.4 Recent developments